BioCentury
ARTICLE | Clinical News

AZD0424: Phase I started

January 21, 2013 8:00 AM UTC

Cancer Research U.K. (London, U.K) began an open-label, U.K. Phase I trial of once-daily oral AZD0424 from AstraZeneca for 28 days in about 96 patients. The dose-escalation Phase Ia portion will evaluate AZD0424 alone and with combination agents, while the Phase Ib portion will evaluate the optimal dose for both AZD0424 and the combination agents. ...